BioCentury | May 25, 2018
Clinical News

MimiVax reports Phase II data for glioblastoma immunotherapy

...data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM...
...in 4Q18. MimiVax spun out of the Roswell Park Comprehensive Cancer Center, which discovered SurVaxM. SurVaxM...
...and immune response Status: Interim Phase II data Milestone: Final Phase II data (4Q18) Sandi Wong SurVaxM (DRU-2017-5947) American...
BioCentury | Oct 15, 2012
Clinical News

SurVaxM: Phase I started

...The institute began an open-label, U.S. Phase I trial to evaluate 4 vaccinations of subcutaneous SurVaxM...
...also receive subcutaneous sargramostim on day 0. Roswell Park Cancer Institute , Buffalo, N.Y. Product: SurVaxM...
Items per page:
1 - 2 of 2